On March 30, 2021, the U.S. Food and Drug Administration approved the revised label for daunorubicin and cytarabine to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes in pediatric patients aged one year and older.
Read the Jazz Pharmaceuticals announcement.
Posted 3/31/2021
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
